Advertisement
|
|
|
|
|
Free Trial
Description: Antony Koblish is Orthovita CEO/President. With a Lead411 subscription, Orthovita email addresses ( @orthovita.com ) of the executives are viewable. Other information includes Antony Koblish email, phone, and extension.
Be sure to check our Linkedin tab on the company page. Typical management titles include VP, Chief, Vice President, Director, manager, & more. Similar names to Koblish can be found at Executive Directory - Koblish.
|
Add Antony Koblish Information
Site Reference: http://www.orthovita.com/investors/pressreleases.aspx#
Antony Koblish chief executive officer of Orthovita, is scheduled to present on Wednesday, November 19th, at 3:30 p.m. Eastern Time, at the St. Regis New York Hotel, 2 East 55th Street at Fifth Avenue, New York, NY. A live audio webcast of the presentation will be available, and can be accessed for 90 days following the conference, by visiting http://www.wsw.com/webcast/lz5/vita. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the chief executive officer of Orthovita, is scheduled to present on Monday, November 10th, at 2:50 p.m. Eastern Time, at the New York Palace Hotel, 455 Madison Avenue, New York, NY. A live audio webcast of the presentation will be available, and can be accessed for 90 days following the conference, by visiting http://www.wsw.com/webcast/rrshq14/vita. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The telephone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 67743061. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning November 4, 2008, at 11:30 a.m. Eastern Time, and ending November 11, 2008, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 67743061. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active chief executive officer of Orthovita, is scheduled to present on Monday, September 22nd, at 9:30 a.m. Eastern Time, at the Grand Hyatt Hotel, 109 East 42nd Street at Grand Central Terminal, New York, NY. A live audio webcast of the presentation will be available as well as a replay which can be accessed three hours after the presentation and until October 25, 2008, by visiting Orthovita’s website, www.orthovita.com and clicking on the Investors/Press Releases section. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute chief executive officer of Orthovita, is scheduled to present on Wednesday, August 13th, at 11:30 a.m. Eastern Time, at the Intercontinental Hotel Boston, 510 Atlantic Avenue, Boston, MA. A live webcast of the presentation will be available and can be accessed one hour after the presentation ends and for 90 days following the conference, by visiting the following website: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=***VITA&item_id=1887727. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS¿ Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The telephone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 54484614. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning August 7, 2008, at 11:30 a.m. Eastern Time, and ending August 14, 2008, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 54484614. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, chief executive officer of Orthovita, is scheduled to present on Thursday, June 12th, at 2:30 p.m. Eastern Time, at The New York Palace Hotel, 455 Madison Avenue, New York, NY. A live audio webcast of the presentation will be available, and can be accessed for 90 days following the conference, by visiting http://www.wsw.com/webcast/needham25/vita. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS¿ Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The telephone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 43786887. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning May 8, 2008, at 11:30 a.m. Eastern Time, and ending May 15, 2008, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 43786887. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, President and Chief Executive Officer of Orthovita. “We also believe VITASURE fits exceptionally well with our sales force’s call pattern focus on spine and orthopedic surgeries and will complement the use of our VITOSS® Bone Graft Substitute product line, including our newly-launched VITOSS Bioactive Foam Bone Graft Substitute product. We are pleased to have the opportunity to launch these two important new products into our specialized sales force in 2008.” Under its distribution agreement with Medafor, Orthovita has the non-exclusive right to sell VITASURE in the spine and orthopedic field in the United States, and certain territories outside of the United States. Medafor has responsibility for manufacturing and maintaining regulatory approvals for the product. The initial term of the agreement is scheduled to expire in December 2013 and Orthovita has the right to renew the agreement for an additional three year period if certain purchase obligations are met during President and Chief Executive Officer of Orthovita, said, “Our in-vivo data indicates that the integration of bioactive glass in VITOSS Bioactive Foam results in more rapid bone repair and healing. We are pleased to offer physicians and their patients a new, enhanced product that combines bioactivity with our market-leading synthetic bone scaffold technology.” As with Orthovita’s VITOSS Foam products, the VITOSS Bioactive Foam product has the ability to soak and hold its own volume in bone marrow aspirate while retaining these biological fluids in pliable and compression resistant forms. VITOSS Bioactive Foam received 510(k) clearance from the U.S. Food and Drug Administration for use in bone grafting procedures in the spine, pelvis and extremities. Pursuant to its contract with Kensey Nash Corporation, Orthovita will pay Kensey Nash to manufacture the VITOSS Bioactive Foam product as well as make certain royalty payments to Kensey Nash based on the net sales President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 34776172. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning March 13, 2008, at 11:30 a.m. Eastern Time, and ending March 20, 2008, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 34776172. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, president and chief executive officer of Orthovita, is scheduled to present on Tuesday, March 4th, at 4:10 p.m. Pacific Time, at The Mission Bay Conference Center at UCSF, 1675 Owens Street, San Francisco, CA. A live audio-only webcast of the presentation will be available by visiting http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2186580 . About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS? Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and president and chief executive officer of Orthovita, is scheduled to present on Thursday, January 31st, at 1:00 p.m. Eastern Time, at The Langham Hotel, 250 Franklin Street, Boston, MA. A live audio webcast of the presentation will be available and can be accessed for 90 days following the conference by visiting http://www.wsw.com/webcast/wa48/vita . About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft President and Chief Executive Officer of Orthovita. FDA clearance of CORTOSS would permit Orthovita to market and sell the material in the United States. CORTOSS has CE Certification for use in the European Union for screw augmentation and for vertebral augmentation. This enables CORTOSS to be sold in the European Union as well as in other countries that have adopted the European Union’s regulatory standards. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the president and chief executive officer of Orthovita, is scheduled to present on Tuesday, January 8th, at 10:00 a.m. Eastern Time, at The New York Palace Hotel, 455 Madison Avenue, New York, NY. An audio webcast of this presentation will be available at http://www.wsw.com/webcast/needham21/vita and will be archived at the same URL for 90 days following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives president and chief executive officer of Orthovita, will participate in a panel discussion entitled “Biomaterials: Helping the Body Regenerate Bone & Tissue” on Thursday, December 13th, at 8:00 a.m. Eastern Time, at The Westin New York at Times Square, 270 West 43rd Street, New York, NY. A live audio-only webcast of the panel discussion will be available and can be accessed for thirty days following the conference by visiting http://www.wsw.com/webcast/rbc84/panel20 . About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which President and Chief Executive Officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 10:00 a.m. to 2:00 p.m. Eastern Standard Time, in the Fontainebleau Room of The St. Regis Hotel, 2 East 55th Street at 5th Avenue, New York, NY. William J. Plovanic, CFA, Managing Director of Equity Research at Canaccord Adams, will be co-hosting the meeting. In addition, the meeting will feature guest speaker Ben B. Pradhan, M.D., M.S.E., from Saint John’s Health Center in Santa Monica, CA, the second largest enrolling site for Orthovita’s 256-patient CORTOSS® VCF clinical trial. Dr. Pradhan is among the top three surgeons in the U.S. with clinical experience using CORTOSS. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 21618688. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning November 6, 2007, at 11:30 a.m. Eastern Time, and ending November 13, 2007, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 21618688. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization President and Chief Executive Officer of Orthovita, said, “This transaction sets our company up for enhanced supply and manufacturing stability of VITAGEL over the long-term by allowing us to have better control of a key product component. In addition, acquiring the production equipment and license will give us the opportunity to integrate a new technology platform and capability into the company.” About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by president and chief executive officer of Orthovita, is scheduled to present on Monday, September 24th, at 11:00 a.m. Eastern Time, at the Grand Hyatt New York Hotel, 109 East 42nd Street, New York, NY. An audio webcast of the presentation will be available three hours after the presentation until October 27, 2007, and may be accessed by visiting the company’s website, www.orthovita.com , and clicking on the conference link under the Press Releases section of the Investors tab. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our president and chief executive officer of Orthovita, is scheduled to present on Wednesday, September 19th, at 9:30 a.m. Pacific Time, at the St. Regis Hotel, 125 Third Street, San Francisco, CA. A live webcast of this presentation will be available at the following link: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=vita&item_id=1645645 . A webcast replay will be available one hour after the presentation and will be archived at the same URL for ninety (90) days following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, President and Chief Executive Officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 10:00 a.m. to 2:00 p.m. Eastern Standard Time, in the Griffin/Robinson Room of The InterContinental Hotel, 510 Atlantic Avenue, Boston, MA. William J. Plovanic, CFA, managing director, equity research from Canaccord Adams will be co-hosting the meeting. In addition, the meeting will feature guest speaker H. Paul Hatten, Jr., M.D., from Indian River Radiology of Vero Beach, Florida, who will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at approximately 11:00 a.m. Eastern Standard Time and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of Orthovita’s CORTOSS President and Chief Executive Officer of Orthovita, is scheduled to present on Tuesday, September 11th, at 8:20 a.m. Eastern Time. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL(R) Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS(R) President and Chief Executive Officer of Orthovita. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS? Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL Surgical Hemostat. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS? Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures. We work jointly with Kensey Nash president and chief executive officer of Orthovita, is scheduled to present on Wednesday, August 8th, at 1:00 p.m. Eastern Time, at the InterContinental Boston Hotel, 510 Atlantic Avenue, Boston, MA. A live webcast of this presentation will be available at the following link: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=VITA&item_id=1609835 . A webcast replay will be available one hour after the presentation and will be archived at the same URL for one year following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are President and CEO of Orthovita. “This substantial investment validates the continuing strength of our product line and the promising progress in our efforts to develop and commercialize innovative new products for spine, orthopedic and biosurgery fields in the years ahead.” In a separate transaction, Orthovita announced that it is repurchasing from a securitization vehicle arranged by Paul Capital Healthcare (formerly Paul Royalty Fund, L.P.) a revenue interest on future sales of certain Orthovita products, including VITOSS®, CORTOSS® and certain spinal structural devices. The Company entered into the revenue interest agreement with Paul Capital Healthcare in October 2001 to fund clinical development and marketing programs for its products. The terms of the 2001 agreement applied to sales of certain products in North America and Europe through 2016, and the revenue interest obligation will terminate upon the closing of the repurchase transaction. The repurchase price for the revenue interest obligation President and CEO of Orthovita, said, “We look forward to more detailed discussions during our earnings conference call scheduled for Tuesday, August 7, at 8:30 a.m. Eastern Time. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offer and sale of the 10% senior secured notes due 2012, the warrants issuable to the purchaser of the 10% senior secured notes due 2012 and the shares of common stock underlying the warrants, and the shares of common stock issuable as partial payment for the repurchase of the revenue interest obligation have not been registered under the United States Securities Act President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host a conference call on Tuesday, August 7, 2007, at 8:30 a.m. Eastern Time, to review and discuss the Company’s financial results for the second quarter 2007. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 7153873. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning August 7, 2007, at 11:30 a.m. Eastern Time, and ending August 14, 2007, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 7153873. About President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 7153873. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning August 7, 2007, at 11:30 a.m. Eastern Time, and ending August 14, 2007, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 7153873. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization president and chief executive officer of Orthovita, is scheduled to present on Thursday, June 28th, at 1:30 p.m. Eastern Time. An audio-only webcast of this presentation will be available at http://www.wsw.com/webcast/jeff18/vita and will be archived at the same URL for 90 days following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL® Surgical president and chief executive officer of Orthovita, Albert J. Pavucek, Jr., Chief Financial Officer, and several members of Orthovita’s management team will present at the meeting scheduled from 1:00 p.m. to 5:00 p.m. Central Time, in the Washington Room of The Sears Tower, 233 South Wacker Drive, Chicago, IL. William J. Plovanic, CFA, managing director, equity research from Canaccord Adams will be co-hosting the meeting. In addition, the meeting will feature guest speaker H. Paul Hatten, Jr., M.D., from Indian River Radiology of Vero Beach, Florida, who will give a presentation entitled “Treatment of Osteoporotic VCF with CORTOSS®: Preliminary Results and Biomechanical Considerations from the First Prospective Trial at a Single Institution”, at approximately 2:00 p.m. and will cover part of a prospective randomized controlled study being conducted under an FDA Investigational Device Exemption (IDE). The study assesses the safety and efficacy of Orthovita’s CORTOSS compared to commercially Chief Executive Officer of Orthovita. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL® Surgical Hemostat, which is an adherent matrix and an impermeable barrier to blood flow. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS® Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to President and Chief Executive Officer, and Albert J. Pavucek, Jr., Chief Financial Officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 6099428. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning May 7, 2007, at 11:30 a.m. Eastern Time, and ending May 14, 2007, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 6099428. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization Orthovita’s Chief Executive Officer, stated, “Paul’s critical skills and experience will make him a great resource for our company. He has a proven management track record, significant manufacturing experience and extensive knowledge of the FDA regulatory process for medical devices. We are very pleased to have him join our Board.” About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone President and Chief Executive Officer, Albert J. Pavucek, Jr., Chief Financial Officer, and Joseph M. Paiva, Chief Business Officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 1380686. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning March 12, 2007, at 11:30 a.m. Eastern Time, and ending March 19, 2007, at 11:59 p.m. Eastern Time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 1380686. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic president and chief executive officer of Orthovita, is scheduled to present on Thursday, March 1st, at 9:00 a.m. Eastern Time, at The Omni Berkshire Place Hotel, 21 East 52nd Street at Madison Avenue, New York, NY. A webcast of this presentation will be available at http://www.wsw.com/webcast/sig4/vita and will be archived at the same URL for 90 days following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by president & chief executive officer of Orthovita. “Pending regulatory clearance, CORTOSS is positioned to be the first new, proprietary biomaterial implant for the treatment of vertebral compression fractures and an alternative to PMMA bone cements available today.” There are an estimated 700,000 osteoporotic vertebral compression fractures in the United States each year. Orthovita believes that the CORTOSS clinical study is the most rigorous trial ever enrolled for vertebral compression fractures of the spine. The prospective, randomized study protocol was developed in accordance with the FDA’s vertebral compression fracture guidance document. CORTOSS has CE Certification for use in the European Union for screw augmentation and for vertebral augmentation. This enables CORTOSS to be sold in the European Union as well as in other countries that have adopted the European Union’s regulatory standards. CORTOSS is not available for sale in the United States and is limited to investigational use. Chief Executive Officer of Orthovita, commented, “Joe has an established record of contributing to the success of Orthovita over the years. In the newly created position of Chief Business Officer, Joe will be responsible for strategic planning, business development and investor relations. Joe’s extensive financial and industry knowledge will be very useful in his new role to help support the growth of the Company and leverage the investment we have made in our biomaterial–focused sales and distribution channel.” Mr. Pavucek has over twenty years of progressive experience in the areas of finance, business planning and operations. Prior to joining Orthovita, Mr. Pavucek served as Vice President, Finance and Operations of PDI, Inc., a biopharmaceutical commercialization partner, starting in 2002. Previously at PDI, Inc., Mr. Pavucek served as Executive Director, Controller since 2001. From 1994 to 2001, he served at Astra Zeneca, L.P. in finance and operations roles of president and chief executive officer of Orthovita, is scheduled to present on Tuesday, February 13th, at 1:10 p.m. Pacific Time, at Marina Village, 1936 Quivira Way, San Diego, CA. This presentation will not be webcast. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL® Surgical Hemostat, which is an adherent matrix and an impermeable barrier to president and chief executive officer of Orthovita, Inc. “This development provides clarity on the required process for submitting our extensive CORTOSS clinical and preclinical data package to the FDA as we seek to bring an important new medical device option to both physicians and patients for the treatment of vertebral compression fractures.” CORTOSS has CE Certification for use in the European Union for screw augmentation and for vertebral augmentation of VCFs of the spine, which enables it to be sold in the European Union as well as in other countries that have adopted the European Union’s regulatory standards. CORTOSS is not approved for use or available for sale in the United States. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials president and chief executive officer of Orthovita, is scheduled to present on Wednesday, January 10th, at 2:00 p.m. Eastern Time, at The New York Palace Hotel, 455 Madison Avenue, New York, NY. A webcast of this presentation will be available at http://www.wsw.com/webcast/needham16/vita and will be archived at the same URL for 30 days following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to President and Chief Executive Officer of Orthovita, is scheduled to participate on the "Motion & Fusion - The Future of Spinal Surgery" panel on Wednesday, December 13th, at 1:30 p.m. Eastern Time, at The Westin New York at Times Square Hotel, 270 West 43rd Street, New York, NY. An audio-only webcast of this presentation will be available at http://www.wsw.com/webcast/rbc62/panel12 and will be archived at the same URL for 30 days following the conference. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute President and Chief Executive Officer, said, “The profit-sharing royalty buyout gives us the potential to increase gross margins on one of our fastest growing products. We plan to further maximize long-term financial benefits from VITAGEL sales by improving manufacturing efficiencies for the product.” About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS® Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, and VITAGEL™ Surgical Hemostat, which is president and chief executive officer, and Joseph M. Paiva, chief financial officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 8401845. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning October 31, 2006, at 11:30 a.m. ET, and ending November 7, 2006, at 11:59 p.m. ET. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 8401845. About the Company Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active, president and chief executive officer of Orthovita, is scheduled to present on Monday, September 25th, at 1:30p.m. Eastern Time, at the Grand Hyatt Hotel, Park Avenue at Grand Central, New York, NY. A live webcast of this presentation will be available at www.ibb.ubs.com by clicking on the "Conferences" link. About the Company Orthovita is a biosurgery company with proprietary biomaterial technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for orthopedic and neurosurgical applications. Our products are used in the regeneration of bone and soft tissue. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-derived bone material to meet a broad range of orthopedic clinical needs in the spine, trauma, joint reconstruction, revision surgery and extremities president and chief executive officer of Orthovita, is scheduled to present on Friday, September 8th, at 12:05p.m. Eastern Time, at the Four Seasons Hotel, 200 Boylston Street, Boston, MA. A live webcast of this presentation will be available at http://www.veracast.com/webcasts/twp/healthcare06/54308266.cfm and will be archived at the same URL for 30 days following the conference. About the Company Orthovita is a biosurgery company with proprietary biomaterial technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for orthopedic and neurosurgical applications. Our products are used in the regeneration of bone and soft tissue. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-derived bone material to meet a broad range of orthopedic clinical needs in the spine, trauma, joint President and CEO of Orthovita. "We look forward to more detailed discussions during the earnings conference call." Operating expenses for the three months ended June 30, 2006 and 2005 were $12,110,000 and $8,304,000, respectively. Operating expenses for the three months ended June 30, 2006 include non-cash net compensation expense of $403,000 related to stock option accounting. These non-cash charges are equivalent to 4% of product sales for the three month period. For the six months ended June 30, 2006 and 2005, operating expenses were $23,268,000 and $16,486,000, respectively. Operating expenses for the six months ended June 30, 2006 include non-cash net compensation expense of $893,000 related to stock option accounting. These non-cash charges are equivalent to 4% of product sales for the 2006 six month period. General & administrative expenses for the three months ended June 30, 2006 increased to $2,234,000 from $1,697,000 for the same period in President and Chief Executive Officer, and Joseph M. Paiva, Chief Financial Officer of Orthovita, will host a conference call at 8:30 a.m. Eastern time on August 4, 2006 to review and discuss the second quarter 2006 financial results. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675; the conference identification number is 2836509. Listeners are advised to dial in ten minutes prior to the scheduled start time for the conference call. The replay of the conference call will be available for one week beginning August 4, 2006, at 11:30 a.m. Eastern time, and ending August 11, 2006, at 11:59 p.m. Eastern time. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 2836509. About the Company Orthovita president and chief executive officer of Orthovita, is scheduled to present on Thursday, September 7th, at 2:00 p.m. Eastern Time, at the Westin New York at Times Square, 270 West 43rd Street, New York, NY. A live webcast of this presentation will be available at http://www.wsw.com/webcast/roth8/vita/ and will be archived at the same URL for 90 days following the conference. About the Company Orthovita is a biomaterials company with proprietary technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for orthopedic and neurosurgical applications. Our products are used in the regeneration of bone and soft tissue. Our near-term commercial business is based on our VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-derived bone material to meet a broad range of orthopedic clinical needs in President and Chief Executive Officer, and Joseph M. Paiva, Chief Financial Officer of Orthovita, will host the call. The phone number to join the conference call from within the U.S. is (888) 815-2919, and from outside the U.S. is (706) 643-3675. The conference identification number is 2836509. Participants should dial in ten minutes prior to the scheduled start time for the conference call. A replay of the conference call will be available for one week beginning August 4, 2006, at 11:30 a.m. ET, and ending August 11, 2006, at 11:59 p.m. ET. You may listen to the replay by dialing within the U.S. (800) 642-1687 or by dialing from outside the U.S. (706) 645-9291. The replay identification number is 2836509. About the Company Orthovita is a biomaterials company with proprietary technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for orthopedic President and Chief Executive Officer of Orthovita. "I am very pleased and proud of our team's performance, particularly from our regulatory affairs, quality and manufacturing groups. We are looking forward to now applying all our energy to driving VITAGEL sales growth." VITAGEL is a composite liquid hemostat used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical. VITAGEL stimulates hemostasis and healing through multiple mechanisms, amplifying the patient's own biology. VITAGEL is approved for use only in conjunction with the CELLPAKER(R) plasma collection system. Upon application, VITAGEL works by combining a thrombin/collagen suspension with the patient's own plasma. The resultant fibrin/collagen clot stems bleeding and provides a robust three-dimensional matrix for soft tissue healing. Orthovita has been distributing VITAGEL and CELLPAKER since January 2005 under a distribution agreement with Angiotech BioMaterials Corp. Pursuant to a chief executive officer of Orthovita, is scheduled to present on Wednesday, June 14th, at 2:30 p.m. Eastern Time, at the New York Palace Hotel, 455 Madison Avenue, New York, NY. A live webcast of this presentation will be available at http://www.wsw.com/webcast/needham15/vita/ and will be archived at the same URL for on-demand listening for 30 days following the conference. About the Company Orthovita is a biomaterials company with proprietary technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for orthopedic and neurosurgical applications. Our products are used in the regeneration of bone and soft tissue healing. Our near-term commercial business is based on our internally developed VITOSS(R) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-derived bone material to meet a broad range of orthopedic clinical
|
|
| Copyright 2010 Lead411 | Santa Barbara, CA |
|
|
|
|
Advertisement
|
